Kylixa (Drospirenone, Ethinylestradiol | Lactose Anhydrous)

Drospirenone provides progestogenic activity with anti‑mineralocorticoid and anti‑androgenic effects, while ethinylestradiol supplies estrogenic stimulation. Together they suppress the hypothalamic‑pituitary‑gonadal axis, lowering LH and FSH secretion, which prevents ovulation, thickens cervical mucus, and creates an endometrium less suitable for implantation.

The dosing regimen for Kylixa is determined by the prescribing healthcare professional. Typically, the product is taken as one tablet daily at the same time each day, but the exact schedule and any missed‑dose instructions are provided by the prescriber.

Kylixa is not intended for use during pregnancy; it is a contraceptive meant to prevent pregnancy. Women who become pregnant while taking the product should discontinue it and consult their physician. Breastfeeding mothers should discuss risks and benefits with their healthcare provider, as hormonal contraceptives may affect milk production.

To order Kylixa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then replies with pricing, availability, shipping details and any necessary import documentation.

Kylixa contains drospirenone, which has anti‑mineralocorticoid and anti‑androgenic properties, potentially offering benefits such as reduced water retention and improved acne compared with some older progestins. Its efficacy in preventing pregnancy is comparable to other combined oral contraceptives, while the side‑effect profile may differ slightly based on the progestin component.

Kylixa tablets should be stored at ambient temperature, below 25 °C, in the original blister pack to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Kylixa is taken orally, usually once daily, at the same time each day. The tablet is swallowed whole with water and should be started on the first day of the menstrual cycle or as directed by a healthcare professional. If a dose is missed, follow the specific missed‑dose instructions provided by the prescriber.

Serious risks associated with Kylixa include venous thromboembolism (deep‑vein thrombosis or pulmonary embolism), arterial thrombosis (stroke or myocardial infarction), hypertension, and severe liver dysfunction. Patients should seek immediate medical attention if they experience unexplained leg pain, shortness of breath, severe headache, visual changes, or jaundice.

Kylixa is contraindicated in women with a history of thromboembolic disorders, estrogen‑dependent tumors, active liver disease, uncontrolled hypertension, or known hypersensitivity to any component of the tablet. It should also be avoided in smokers over 35 years of age and in individuals taking medications that markedly increase clotting risk.